12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

UCB, Wilex deal

UCB reacquired from Wilex an undisclosed preclinical UCB antibody program in indications outside oncology. Wilex retains rights to develop the program in oncology indications. Wilex received an exclusive,...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >